Sartorius Ag · XETR:SRT
Sartorius — Investor Day (March 2026)
39 slides from Sartorius's investor day presentation, Mar 17, 2026
Slide 1: Sartorius and Sartorius Stedim Biotech Capital Markets Day 2026
Sartorius and Sartorius Stedim Biotech Capital Markets Day 2026 March 17, 2026
Slide 2: Note
Note This presentation contains statements concerning the future performance of Sartorius Group and Sartorius Stedim Biotech. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will act
Slide 3: Agenda
Sartorius Group Agenda Strategy update & Financial perspective 09:00 Executive Board 11:20 Coffee break Spotlight “Leveraging AI to drive product innovation and operational excellence” 11:35 CTO & Operations Management 12:05 Lunch Spotlight “Pioneering the future of Single-Use bioprocessing” 12:50 B
Slide 4: Strategy update & financial perspectives
Sartorius Group Strategy update & financial perspectives Dr. Michael Grosse Dr. Florian Funck CEO CFO Speakers Dr. René Fáber Dr. Alexandra Gatzemeyer Head of BPS Head of LPS Division & CEO SSB Division 4 Capital Markets Day 2026
Slide 5: What we are building on
What we are building on YRTORILS
Slide 6: Anchored in purpose – Ambitious to shape the future
Sartorius Group Anchored in purpose – Ambitious to shape the future Our Better health for more people. Purpose We empower biopharma customers to accelerate drug Our development and enhance manufacturing efficiency Mission for better therapies and more affordable medicine. Our Simplifying Progress Pr
Slide 7: A leading biologics pure play with unique strengths in single-use
Sartorius Group A leading biologics pure play with unique strengths in single-use Strong focus Highly differentiated end-to-end portfolio; leading market positions on biopharma Unique Deep scientific, application and regulatory expertise know-how Trusted Superior and consistent quality and global te
Slide 8: Compelling business profile in a ten years perspective
Sartorius Group Compelling business profile in a ten years perspective Track record of profitable growth above market High revenue share with Life Sciences customers Sales Ø Annual margin ~12% CAGR ~60bps expansion 2025 ~85% Revenue share today ~€3.5bn 29.7 % 2015 ~€1.1bn 23.6% 2015 2025 Sales reven
Slide 9: Resilient global footprint supporting customers worldwide
Sartorius Group Resilient global footprint supporting customers worldwide Helsinki Kajaani Havant Glasgow Umeå Sales revenue by region Stonehouse Royston Malmø Nottingham Göttingen Ann Arbor Cergy Liège Bielefeld Jena Beijing EMEA Americas Illkirch Ulm Guxhagen Marlborough Lourdes Loos Freiburg Brat
Slide 10: Continuous portfolio expansion through innovation
Sartorius Group Continuous portfolio expansion through innovation Strengthened portfolio in three key areas mainly through M&A Strong innovation engine Bioanalytics ▪ Greater focus on biopharma research and ACM ▪ Increased cross-selling potential Own product development in areas of core competencies
Slide 11: Addressing the complex and regulated biopharma value chain
Sartorius Group Addressing the complex and regulated biopharma value chain 1 Molecule development 2 Cell line & process development Identification and design of a therapeutic molecule Creation of a stable cell line; definition of a robust manufacturing process 3 Upstream & downstream production Sart
Slide 12: A strong platform for biopharma research and analytical characterization and quality control
Sartorius Group A strong platform for biopharma research and analytical characterization and quality control Our ambition Differentiated BioA and cell model solutions with strong market Accelerate drug development positions; premium supplier and innovator for lab essentials Bioanalytical instruments
Slide 13: A scalable single-use platform for efficient biopharma manufacturing
Sartorius Group A scalable single-use platform for efficient biopharma manufacturing Our ambition Scalable end-to-end solutions for all biopharmaceutical modalities; More efficient bioprocessing Market leader in single-use technologies Design safe and flexible Media & reagents Bioreactors processes
Slide 14: Attractive business model with high share of recurring revenue
Sartorius Group Attractive business model with high share of recurring revenue Steady recurring revenues supported by validated manufacturing processes and equipment installations ~80% Consumables & reagents Software Service Recurring revenue FY 2025 figures 14 Capital Markets Day 2026
Slide 15: Regulatory validation as a foundation for the resilient Sartorius business model
Sartorius Group Regulatory validation as a foundation for the resilient Sartorius business model Customer Molecule Cell line & process Clinical trials Commercial workflow development development production % of revenue ~10% ~10% ~25% ~55% Sales Seed business Win the spec Scale up process Business st
Slide 16: Strong market fundamentals
Strong market fundamentals YRTORILS
Slide 17: Sustained strong market fundamentals
Sartorius Group Sustained strong market fundamentals Growing and aging Growing pharma Shift in medicine Increasing number of population1 market2 to biologics2 drug approvals2,3 >1.6bn ~5% p.a. ~57% 2x Estimated number of growth of global share of biologics in number of approvals4 in people aged 65+
Slide 18: Broad growth of biologics; rising relevance of new modalities
Sartorius Group Broad growth of biologics; rising relevance of new modalities mAbs remain dominant; biosimilars, AT and next gen antibodies Large number of molecules in pipeline: with strong growth from small base New modalities account for ~50% today Revenue by modality (€ bn)1 Number of molecules
Slide 19: R&D and production volumes as structural market growth drivers
Sartorius Group R&D and production volumes as structural market growth drivers Addressable market CAGR mid-term1 Opportunities ▪ Biopharma R&D and production volumes continue to grow, driven Group 7-9% by expanding pipelines, drug approvals, and rising patient demand ▪ Increasing complexity and dive
Slide 20: Single-use (SU) and process intensification: Reshaping bioprocessing
Sartorius Group Single-use (SU) and process intensification: Reshaping bioprocessing Biologics manufacturing is evolving Modality mix supports adoption: SU is preferred platform for majority of pipeline modalities ▪ More single-use, even at commercial scale ▪ More intensified, automated, and data-dr
Slide 21: Biopharma R&D is evolving – new business opportunities emerging
Sartorius Group Biopharma R&D is evolving – new business opportunities emerging Automation and AI reshape lab workflows Advanced cell models replacing animal testing Smart instruments Opportunity Driven by regulatory shifts away from animal testing Robotic automation Emerging Predictive, human-relev
Slide 22: How we shape the future
How we shape the future YRTORILS
Slide 23: Strengthening Sartorius' competitive edge
Sartorius Group Strengthening Sartorius’ competitive edge Simplifying progress Financial ambition Profitable growth above market, enhanced cash generation, reduced leverage Strategic Portfolio Customer experience Excellence & efficiency initiatives How to add value to customers How to engage with cu
Slide 24: Sharpening portfolio for above-market growth
Sartorius Group Sharpening portfolio for above-market growth Grow the core Our Goal ▪ Focus on high-value, mission Grow ambitiously and expand market critical applications and/or high leadership in our core businesses growth areas ▪ Capture greater share of wallet We stay focused on ▪ Focus on organ
Slide 25: Growing the core across mission-critical bioprocessing and cell analytics
Sartorius Group Growing the core across mission-critical bioprocessing and cell analytics ▪ Build on our pioneering position to Pionic Ambr lead single use manufacturing Process Intensification ▪ Maintain leadership through continuous innovation of established product lines Sartopore Celsius Core Si
Slide 26: Advancing future businesses beyond the core: Additional growth vectors
Sartorius Group Advancing future businesses beyond the core: Additional growth vectors Specialized solutions built on differentiated raw materials, analytics, and instrument expertise ATS1 Validated human-relevant toxicity testing with an integrated portfolio of advanced cell models, ACM/NAMs2 assay
Slide 27: Enhancing customer experience across the end-to-end journey
Sartorius Group Enhancing customer experience across the end-to-end journey Customer expectations across the life science industry Initiatives to enhance customer experience Short lead times, convenient product customization Improving lead times, delivery performance and configurability of our produ
Slide 28: Evolving into a more cost-efficient, digitalized and lean organization
Sartorius Group Evolving into a more cost-efficient, digitalized and lean organization Operations transformation to achieve best-in-class supply chain performance, product and service quality Factory of the Network Simplify Strengthen future optimization operations sourcing more automation, resilien
Slide 29: Delivering an attractive financial profile
Delivering an attractive financial profile
Slide 30: 2026 as a transition year towards mid-term growth ambition
Sartorius Group 2026 as a transition year towards mid-term growth ambition Sales revenue growth, ul. EBITDA margin 12 31.5 What we currently see 10 +5-9% 31 +7.6% 8 ▪ Market is showing signs of gradual improvement 30.5 ▪ Equipment business stabilizing, becoming less dilutive 6 30 to growth 4 Sligthl
Slide 31: Sustained outperformance supported by market trends
Sartorius Group Sustained outperformance supported by market trends Sartorius mid-term ambition2 Addressable market Sartorius key drivers Above-market Organic sales revenue ul EBITDA margin CAGR mid-term1 of outperformance growth p.a. growth p.a. in cc expansion p.a. Sartorius ▪ Focus on high-growth
Slide 32: Long-term margin upside embedded in the business model
Sartorius Group Long-term margin upside embedded in the business model Expected contribution to Mid-term key assumptions Share of cost positions margin development ▪ Increasing capacity utilization; growing 2019 2025 2026e Mid-term consumables contribution Sales 100% 100% ▪ Cost improvements driven
Slide 33: Higher efficiency through continuous improvement mindset and scalable growth platforms
Sartorius Group Higher efficiency through continuous improvement mindset and scalable growth platforms Efficiency program Cost savings of ~€100m with positive margin effects in 2025 2024 as a base Continuous based on lean/CI thinking to improve cost structures from year to year efficiency initiative
Slide 34: Substantial investments support resilient footprint and future growth
Sartorius Group Substantial investments support resilient footprint and future growth Key Focus Areas Freiburg Cell culture reagents Göttingen Songdo Global resilience Ann Arbor Membranes, filters, R&D Filters, cell culture media, bags, laboratories, training Competence center Redundant capacities c
Slide 35: Strong cash generation and financial flexibility
Sartorius Group Strong cash generation and financial flexibility Capex Free Cash Flow in % of revenue 2025 Mid-term Major capex projects 2026 ~12.5% Ul EBITDA margin 29.7% ~50-75bps p.a.1 Songdo, South Korea Freiburg, Germany hsd NWC in % of sales 13.7% Slightly down Regular capex composition Capex
Slide 36: Committed to investment-grade rating; strong focus on cash generation
Sartorius Group Committed to investment-grade rating; strong focus on cash generation Continued deleveraging after intense M&A phase Polyplus Disciplined capital deployment DHR Novasep LS assets Chroma. MATTEK ▪ Organic deleveraging the top priority WaterSep Albumedix ▪ Capex discipline and focused
Slide 37: Diversified, long-term debt financing
Sartorius Group Diversified, long-term debt financing Main financing instruments Duration profile of debt financing ▪ Committed to investment in EUR million; as of December 2025 without synd. revolving credit facility grade rating: currently, BBB- Syndicated Bonds 1.836 (stable) IG rating from S&P c
Slide 38: Sustainable value creation remains well on track
Sartorius Group Sustainable value creation remains well on track Proven strengths that continue to matter ▪ Addressing attractive biopharma end markets with high entry barriers and strong structural growth drivers ▪ Biologics pure-play with a focus on single-use, uniquely positioned to capture above
Slide 39: Q&A
Q&A YRTORILS